Drug Profile
Research programme: antibody-drug conjugates - Advanced Proteome Therapeutics/ Heidelberg Pharma Research
Alternative Names: Antibody-amanitin conjugateLatest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Advanced Proteome Therapeutics; Heidelberg Pharma
- Developer Advanced Proteome Therapeutics; Heidelberg Pharma Research
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Nov 2023 Heidelberg Pharma Research has patent protection for site-specific ATAC conjugates in Europe
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)